Pure Biologics Spólka Akcyjna (PUR.WA)

PLN 9.38

(0.7%)

Net Income Summary of Pure Biologics Spólka Akcyjna

Pure Biologics Spólka Akcyjna's latest annual net income in 2023 was -35.69 Million PLN , down -35.35% from previous year.
Pure Biologics Spólka Akcyjna's latest quarterly net income in 2024 Q2 was -2.99 Million PLN , up 39.8% from previous quarter.
Pure Biologics Spólka Akcyjna reported an annual net income of -26.37 Million PLN in 2022, down -101.76% from previous year.
Pure Biologics Spólka Akcyjna reported an annual net income of -13.07 Million PLN in 2021, down -7.98% from previous year.
Pure Biologics Spólka Akcyjna reported a quarterly net income of -4.97 Million PLN for 2024 Q1, up 55.38% from previous quarter.
Pure Biologics Spólka Akcyjna reported a quarterly net income of -7.59 Million PLN for 2023 Q3, up 23.38% from previous quarter.

Annual Net Income Chart of Pure Biologics Spólka Akcyjna (2023 - 2016)

Historical Annual Net Income of Pure Biologics Spólka Akcyjna (2023 - 2016)

Year	Net Income	Net Income Growth
2023	-35.69 Million PLN	-35.35%
2022	-26.37 Million PLN	-101.76%
2021	-13.07 Million PLN	-7.98%
2020	-12.1 Million PLN	-157.29%
2019	-4.7 Million PLN	-582.5%
2018	-689.34 Thousand PLN	-67.02%
2017	-412.72 Thousand PLN	4.67%
2016	-432.92 Thousand PLN	0.0%

Year	Net Income	Net Income Growth
2024 Q2	-2.99 Million PLN	39.8%
2024 Q1	-4.97 Million PLN	55.38%
2023 Q3	-7.59 Million PLN	23.38%
2023 Q4	-11.13 Million PLN	-46.61%
2023 Q1	-7.78 Million PLN	-10.86%
2023 Q2	-9.91 Million PLN	-27.44%
2023 FY	-35.69 Million PLN	-35.35%
2022 Q2	-5.79 Million PLN	20.28%
2022 Q4	-7.01 Million PLN	-8.09%
2022 FY	-26.37 Million PLN	-101.76%
2022 Q1	-7.27 Million PLN	-949.06%
2022 Q3	-6.49 Million PLN	-12.03%
2021 Q1	-3.13 Million PLN	28.33%
2021 FY	-13.07 Million PLN	-7.98%
2021 Q3	-4.27 Million PLN	-16.7%
2021 Q4	-693 Thousand PLN	83.79%
2021 Q2	-3.66 Million PLN	-16.99%
2020 Q4	-4.37 Million PLN	-65.47%
2020 FY	-12.1 Million PLN	-157.29%
2020 Q2	-2.63 Million PLN	-64.31%
2020 Q3	-2.64 Million PLN	-0.27%
2020 Q1	-1.6 Million PLN	20.45%
2019 Q2	-1.23 Million PLN	-247.67%
2019 Q1	-354.69 Thousand PLN	-31.18%
2019 FY	-4.7 Million PLN	-582.5%
2019 Q4	-2.01 Million PLN	-113.35%
2019 Q3	-944.54 Thousand PLN	23.41%
2018 Q3	-240.68 Thousand PLN	-114.34%
2018 FY	-689.34 Thousand PLN	-67.02%
2018 Q1	-65.98 Thousand PLN	12.27%
2018 Q2	-112.29 Thousand PLN	-70.18%
2018 Q4	-270.38 Thousand PLN	-12.34%
2017 Q3	199.72 Thousand PLN	0.0%
2017 FY	-412.72 Thousand PLN	4.67%
2017 Q4	-75.21 Thousand PLN	-137.66%
2016 FY	-432.92 Thousand PLN	0.0%

Peer Net Income Comparison of Pure Biologics Spólka Akcyjna

Name	Net Income	Net Income Difference
Bioceltix S.A.	-13.68 Million PLN	-160.777%
BIOTON S.A.	2.27 Million PLN	1668.967%
Captor Therapeutics Spolka Akcyjna	-70.58 Million PLN	49.43%
Mabion S.A.	41.26 Million PLN	186.491%
Molecure S.A.	-18.3 Million PLN	-94.962%
NanoGroup S.A.	-7.88 Million PLN	-352.406%
Pharmena S.A.	28.94 Million PLN	223.334%
Poltreg S.A.	-13.55 Million PLN	-163.405%
Ryvu Therapeutics S.A.	-92.11 Million PLN	61.249%
Synthaverse S.A.	4.75 Million PLN	850.189%
Urteste S.A.	-5.58 Million PLN	-538.99%